What does CASSIPHARMA do?

CASSIPHARMA is a pharmacy in Gent. Private Limited, started on 12 June 2002, 1 establishment.

What is the address of CASSIPHARMA?

The registered office of CASSIPHARMA is located at Koning Boudewijnstraat 25, 9000 Gent.

Is CASSIPHARMA still active?

Yes. According to the CBE (30 October 2026) CASSIPHARMA is active, legal situation “Normale toestand”, started on 12 June 2002.

Is CASSIPHARMA registered on Peppol?

Yes, CASSIPHARMA is registered on the Peppol network with ID 0208:0477736777.

What is the enterprise number of CASSIPHARMA?

The enterprise number of CASSIPHARMA is BE0477736777.

When was CASSIPHARMA founded?

CASSIPHARMA was founded on 12 June 2002.

Who are the directors of CASSIPHARMA?

According to the 2025 annual accounts, the directors of CASSIPHARMA are: Dokriphar BV.

Is CASSIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 June 2002; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CASSIPHARMA make in 2025?

CASSIPHARMA posted a profit after taxes of € 8,177 in financial year 2025.

What is the revenue of CASSIPHARMA?

As a small company, CASSIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 167,759.

How much does an employee at CASSIPHARMA earn?

The average wage cost per full-time employee at CASSIPHARMA was € 76,400 in 2025: staff costs of € 160,443 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CASSIPHARMA have?

According to the 2025 annual accounts, CASSIPHARMA has 2.1 full-time equivalents (FTE).

CASSIPHARMA (Private Limited) - Gent - BE0477736777

Dossier CASSIPHARMA, printed on 30 October 2026 from databakkes.be/en/0477736777/cassipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CASSIPHARMA from Gent, company number BE0477736777, closed financial year 2025 with a result of € 8,177 after tax. For that financial year CASSIPHARMA recorded a gross margin of € 167,759 and equity of € 217,796. Compared with financial year 2024, the result moved from € -15,497 to € 8,177. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 217,796

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 8,177

▲ still € 15,497 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 294,389

▲ 3% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 7,400 paid out

90 % of the profit went to the shareholders, mostly to Dokriphar (99 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 160,443

▲ 8% vs 2024

€ 76,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 456

▼ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 88,180

▼ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 23,902

▲ 137% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 273,983 Gross margin 2022: € 273,983 First fiscal year in the series	€ 69,739 Gross margin 2023: € 69,739 ▼ 75% vs 2022 (€ 273,983) Unfavourable step	€ 132,499 Gross margin 2024: € 132,499 ▲ 90% vs 2023 (€ 69,739) Favourable step	€ 167,759 Gross margin 2025: € 167,759 ▲ 27% vs 2024 (€ 132,499) Favourable step	▲ 27%
Profit after taxes	€ 51,572 Profit after taxes 2022: € 51,572 First fiscal year in the series	€ -71,001 Profit after taxes 2023: € -71,001 ▼ € 122,574 vs 2022 (€ 51,572) Unfavourable step	€ -15,497 Profit after taxes 2024: € -15,497 ▲ € 55,504 vs 2023 (€ -71,001) Favourable step	€ 8,177 Profit after taxes 2025: € 8,177 ▲ € 23,675 vs 2024 (€ -15,497) Favourable step	▲ € 23,675
Equity	€ 719,664 Equity 2022: € 719,664 First fiscal year in the series	€ 232,517 Equity 2023: € 232,517 ▼ 68% vs 2022 (€ 719,664) Unfavourable step	€ 217,019 Equity 2024: € 217,019 ▼ 7% vs 2023 (€ 232,517) Unfavourable step	€ 217,796 Equity 2025: € 217,796 Unchanged (€ 217,019) Favourable step
Total debts	€ 976,994 Total debts 2022: € 976,994 First fiscal year in the series	€ 397,082 Total debts 2023: € 397,082 ▼ 59% vs 2022 (€ 976,994) Favourable step	€ 338,948 Total debts 2024: € 338,948 ▼ 15% vs 2023 (€ 397,082) Favourable step	€ 331,191 Total debts 2025: € 331,191 ▼ 2% vs 2024 (€ 338,948) Favourable step	▼ 2%
Cash	€ 142,275 Cash 2022: € 142,275 First fiscal year in the series	€ 306,418 Cash 2023: € 306,418 ▲ 115% vs 2022 (€ 142,275) Favourable step	€ 285,858 Cash 2024: € 285,858 ▼ 7% vs 2023 (€ 306,418) Unfavourable step	€ 294,389 Cash 2025: € 294,389 ▲ 3% vs 2024 (€ 285,858) Favourable step	▲ 3%
Retained profit	€ 701,064 Retained profit 2022: € 701,064 First fiscal year in the series	€ 224,672 Retained profit 2023: € 224,672 ▼ 68% vs 2022 (€ 701,064) Unfavourable step	€ 209,174 Retained profit 2024: € 209,174 ▼ 7% vs 2023 (€ 224,672) Unfavourable step	€ 209,952 Retained profit 2025: € 209,952 Unchanged (€ 209,174) Favourable step
Dividend	€ 44,000 Dividend 2022: € 44,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 44,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 7,400 Dividend 2025: € 7,400 Unchanged (€ 0) Unchanged
Bank debt	€ 1 Bank debt 2022: € 1 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 1) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,696,657 Balance sheet total 2022: € 1,696,657 First fiscal year in the series	€ 629,599 Balance sheet total 2023: € 629,599 ▼ 63% vs 2022 (€ 1,696,657) Unchanged	€ 555,967 Balance sheet total 2024: € 555,967 ▼ 12% vs 2023 (€ 629,599) Unchanged	€ 548,988 Balance sheet total 2025: € 548,988 ▼ 1% vs 2024 (€ 555,967) Unchanged	▼ 1%
Employees (FTE)	2.6 Employees (FTE) 2022: 2.6 First fiscal year in the series	3 Employees (FTE) 2023: 3 ▲ 0.4 vs 2022 (2.6) Unchanged	2.1 Employees (FTE) 2024: 2.1 ▼ 0.9 vs 2023 (3) Unchanged	2.1 Employees (FTE) 2025: 2.1 Unchanged (2.1) Unchanged

Key figures of CASSIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to CASSIPHARMA?

What happened at CASSIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: profit of € 8,177. Source: NBB ↗
Aug 14, 2002 New establishment in Gent. KBO
Jun 12, 2002 Start of the company according to the CBE. KBO

In short

From € 51,572 profit in 2022 to € 8,177 profit in 2025.

Paid € 7,106 in corporate taxes since 2022.

Best year ever: 2022, with € 51,572 profit.

On average € 79,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Dokriphar 99%

The stake of Dokriphar comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CASSIPHARMA

Behind CASSIPHARMA is Dokriphar BV. The shares are held by Dokriphar (99%).

Directors

According to the 2025 annual accounts

Dokriphar BV

Director · represented by Dominiek SIMOENS

Also active at: 3-FOLIA, DOMICAPHARMA

Shareholders

Dokriphar

99%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Koning Boudewijnstraat 25

9000 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

CASSIDOK

Vereniging van mede-eigenaars van de residentie VALAND te 9000 Gent, Koning Boudewijnstraat 25

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0477.736.777

VAT number

BE 0477.736.777

Registered office

Koning Boudewijnstraat 25, 9000 Gent

Names & denominations

CASSIPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 June 2002

Peppol

Active · Active since 7 Oct 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

CASSIPHARMA

Financials

What happened to CASSIPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions